These large pharmacy stock bottles contain Calomel, Rhubarb and Colocynth Compound tablets, a purgative medication manufactured by The S. E. Massengill Company of Bristol, Tennessee. Each bottle originally contained 1,000 sugar-coated white tablets, intended for dispensing by physicians and pharmacists.

The formulation represents a typical early twentieth-century compound laxative. Each tablet contained calomel (a mercury compound) combined with several botanical purgatives including rhubarb, aloe, colocynth extract, myrrh, and ipomoea resin. The preparation was designed to stimulate the bowels aggressively and was prescribed for constipation, digestive complaints, and the vague diagnosis historically referred to as “biliousness.”

Calomel (mercurous chloride) had been widely used in Western medicine since the eighteenth century and was once considered one of the most reliable therapeutic agents available to physicians. By the early twentieth century, however, its toxicity was increasingly recognized. Mercury compounds were known to cause excessive salivation, gum destruction, neurological symptoms, and other signs of mercury poisoning when used chronically.

The label on these bottles reflects the growing awareness of these risks. It includes a warning that prolonged use of laxatives—particularly those containing mercury—could lead to dependency or mercury poisoning. Such cautionary language became increasingly common after early federal drug regulation began requiring more transparent labeling of pharmaceutical ingredients.

These bottles illustrate a transitional period in American pharmaceutical history, when traditional mercury-based remedies were still widely available but were gradually being phased out as modern pharmacology developed safer alternatives.